Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTN-0051: Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment
NCT02032433Phase 4Completed
- Sponsor
- NYU Langone Health
- Start
- Jan 2014
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in opioid use disorder (OUD) comparing Extended-Release Naltrexone with Buprenorphine-Naloxone (2 arms). Primary endpoint: Time to Relapse. Started Jan 2014; status: completed.
02
Drugs
naltrexonebuprenorphine + naloxone
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT02032433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02032433.